FdaApproval

Roche's (RHHBY) blockbuster cancer drug, Avastin, is up for review by the U.S. Food and Drug Administration next month. If the FDA follows its advisory panel's recommendation from last month, it may revoke its approval of Avastin for the treatment of advanced breast cancer.

Back in early July, Human Genome Sciences Inc. (HGSI) shares jumped over 230 percent in one day after the pharmaceutical company said its experimental lupus drug had succeeded in a late-stage clinical trial, silencing many of its skeptics. If you decided then that a 230 percent move was all that...